Strong Revenue Growth:
Revenue momentum is portrayed as rapid, with inclusion on the 2026 Inc. 5000 and statements that ARR has risen markedly since 2022. Milestones across 2024–2026 indicate sustained scaling rather than a one‑off spike.
Investor Backing & Capital Strength:
Financing rounds of $45M (2024) and $80M (2026) brought total capital to about $160M and a valuation near $955M, signaling ample resources to execute. The company links this capital to expansion of AI capabilities and data products.
Strong Market Position & Advantage:
Customer footprint reportedly surpassed 500 by mid‑2026, including penetration into 16 of the top 20 MedTech companies with named logos like BD, Olympus, and Teleflex. This depth of enterprise adoption suggests meaningful competitive positioning within MedTech.
